Relapse in patients with schizophrenia has devastating repercussions, including worsening
symptoms, impaired functioning, cognitive deterioration and reduced quality of life. This …

Introduction Schizophrenia is a chronic and debilitating mental illness characterised by
periods of relapse that require resource intensive management. Quantifying the cost of …

Cariprazine, a dopamine D 3/D 2 receptor partial agonist with preference for D 3 receptors,
has demonstrated efficacy in randomized controlled trials in schizophrenia. This …

Background Previous research revealed an absence of any previous studies reporting the
impact that pandemics may have on psychotic symptomology, nor on the physical health of …

Background: Inpatient care to manage relapse of patients with schizophrenia contributes
greatly to the overall financial burden of treatment. The present study explores to what extent …

Background For patients with schizophrenia, relapse is a recurring feature of disease
progression, often resulting in substantial negative impacts for the individual. Although a …

In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible
Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with …

Evaluating the rehabilitation status of individuals with serious mental illnesses (SMI)
necessitates a comprehensive analysis of multimodal data, including unstructured text …

In the present study, various outcomes over 3-year period in patients with early stage
psychosis including remission, recovery, relapse and medication adherence were …

The Remission in Schizophrenia Working Group has recently proposed a consensus
definition of remission in schizophrenia and, based on this definition, has developed specific …